eli lilly obesity - Search News

Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast.

YAHOO!Finance · 1d

Eli Lilly’s earnings, shares lifted by obesity drug sales

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for its weight loss medicines in January.

The Financial Times · 1d

Eli Lilly expects to beat profit forecasts on obesity drug demand

The world’s biggest drugmaker Eli Lilly has forecast that profits for the year will beat expectations, after two choppy quarters when disappointing sales of its blockbuster weight-loss drugs led to sharp sell-offs in its shares.

Reuters on MSN · 1d

Lilly forecasts 2025 profit growth after recent weight-loss drug worries

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, providing some relief to investors after another quarter of sales miss for its popular diabetes and weight-loss treatments.

CNBC on MSN · 1d

Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars

CNBC's Angelica Peebles joins 'Squawk Box' to report on the company's quarterly earnings results.

22hon MSN

Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

FierceBiotech20h

Eli Lilly's next R&D focus: Testing incretin meds in neuro, immunology fields

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

12d

Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

22hon MSN

The Obesity Market Is Growing Just Fine. But Investors Want to Know What’s Next

Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...

12h

Eli Lilly Q4: Don't Miss Out On 2025 Gains, There's Limited Space Left

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

FierceBiotech1d

UPDATED: Eli Lilly lops Alzheimer's and obesity assets from pipeline in Q4 update

In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs by partnering with KeyBioscience in 2017. At one time, the Big Pharma was ...

With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?

Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, ...

FiercePharma21h

Eli Lilly logs massive Q4 revenue jump—but it's not just thanks to Mounjaro and Zepbound

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help ...

BioSpace22h

After Lilly Powers Up Zepbound Supply, Analyst Wonders if Build Out Is ‘Over Our Skis’

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results